Soleus Capital Management L.P. Buys New Holdings in Inhibikase Therapeutics, Inc. (NYSE:IKT)

Soleus Capital Management L.P. purchased a new stake in shares of Inhibikase Therapeutics, Inc. (NYSE:IKT - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 6,325,000 shares of the company's stock, valued at approximately $20,556,000. Inhibikase Therapeutics accounts for about 1.3% of Soleus Capital Management L.P.'s holdings, making the stock its 23rd largest position. Soleus Capital Management L.P. owned about 9.12% of Inhibikase Therapeutics at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Squarepoint Ops LLC purchased a new position in Inhibikase Therapeutics in the fourth quarter valued at about $92,000. Stonepine Capital Management LLC purchased a new position in Inhibikase Therapeutics in the fourth quarter valued at about $3,680,000. OMERS ADMINISTRATION Corp purchased a new position in Inhibikase Therapeutics in the fourth quarter valued at about $177,000. Millennium Management LLC purchased a new position in Inhibikase Therapeutics in the fourth quarter valued at about $462,000. Finally, Jefferies Financial Group Inc. purchased a new position in Inhibikase Therapeutics in the fourth quarter valued at about $48,000. Hedge funds and other institutional investors own 3.81% of the company's stock.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a "neutral" rating on shares of Inhibikase Therapeutics in a research note on Friday, March 28th.

Inhibikase Therapeutics Trading Down 3.8%

Shares of IKT stock traded down $0.07 during trading hours on Friday, reaching $1.77. 148,858 shares of the company's stock were exchanged, compared to its average volume of 233,546. Inhibikase Therapeutics, Inc. has a 1 year low of $1.12 and a 1 year high of $4.20. The stock has a market cap of $131.59 million, a PE ratio of -0.66 and a beta of 1.01. The stock's fifty day moving average price is $2.07 and its two-hundred day moving average price is $2.47.

About Inhibikase Therapeutics

Inhibikase Therapeutics, Inc, a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract.